Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma

Next Previous
X
Search
Trial Profile

Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Olaparib (Primary)
  • Indications Carcinoma; Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker
  • Acronyms olaparib

    • Most Recent Events

    • 01 Dec 2020 Protocol was amended to increase patient accrual, for enrollment of oligometastatic patients with a good response to induction chemotherapy and radical treatment of the oligometastasis in the (SC) RT arm.
    • 01 Dec 2020 Results published in the Clinical Cancer Research
    • 13 Mar 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top